Imagine benefiting U.S. clinicians and patients with revolutionizing the conventional remote therapeutic monitoring (RTM) platform by AI-powered digital biomarker that enables effective & trackable at-home neuromuscular rehabilitation. exoRehab provides not only web & mobile applications, but also a lightweight, FDA-registered wearable embedded with surface EMG and 9-axis IMU sensors to capture objective muscle-activation and joint-kinematic data; encrypted Bluetooth sends readings to a HITRUST-aligned AWS cloud where our proprietary AI converts them into digital biomarkers to support sarcopenia diagnosis and more. Along with the sensor, exoRehab lets clinicians prescribe exercises, monitor progress, and automatically timestamps the activities to prepare claim documentation for Medicare without additional staff while generating ancillary revenue under CPT 98975-98981. The system has been iterated through more than twenty clinician interviews, usability tests, and pilot deployments in the U.S. and Korea. exoRehab conforms to ISO 13485 medical device quality management, FDA CGMP, and FCC requirements slated for launch immediately after CES 2026.